20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
ATAI Life Sciences BV (ATAI) operates in the BIOTECHNOLOGY industry and is headquartered in New York, United States with about 99 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, ATAI reported $4M in revenue and ($660M) in net income.
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments. The company develops rapid-acting and durable therapies for conditions with limited treatment options.
Interactive charts & full statements → Open the ATAI valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $4M | $4M | $0M | $0M | $0M | $20M | $20M | $0M |
| Gross Profit | $4M | $3M | $0M | $0M | $0M | $20M | $0M | $0M |
| Gross Margin % | 86.2% | 75.2% | -53.6% | -1.6% | 27.9% | 99.8% | -0.1% | — |
| Operating Income (EBIT) | ($146M) | ($100M) | ($103M) | ($125M) | ($144M) | ($120M) | ($104M) | ($18M) |
| Operating Margin % | -3274.3% | -2439.7% | -33341.2% | -39958.9% | -61987.1% | -590.5% | -523.9% | — |
| Net Income | ($668M) | ($660M) | ($149M) | ($40M) | ($152M) | ($168M) | ($170M) | ($14M) |
| Net Margin % | -14938.4% | -16142.0% | -48464.0% | -12810.2% | -65401.3% | -823.6% | -854.3% | — |
| EBITDA | ($679M) | ($658M) | ($147M) | ($40M) | ($150M) | ($178M) | ($104M) | ($18M) |
| Earnings Per Share (EPS) | $-1.85 | $-2.91 | $-0.93 | $-0.25 | $-0.98 | $-1.04 | $-1.11 | $-0.09 |
| Shares Outstanding (M) | 361M | 227M | 160M | 159M | 156M | 161M | 153M | 153M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $2M | $1M | $1M | $1M | $1M | $2M | $0M | $0M |
| Gross Profit | $1M | $1M | $1M | $1M | $0M | $1M | ($18M) | $0M |
| Gross Margin % | 87.4% | 82.5% | 100.0% | 68.9% | 68.4% | 86.1% | 358060.0% | -107.5% |
| Operating Income (EBIT) | ($44M) | ($31M) | ($43M) | ($28M) | ($25M) | ($20M) | ($30M) | ($23M) |
| Operating Margin % | -2590.4% | -3239.1% | -4032.1% | -3796.5% | -3515.0% | -1310.0% | 605300.0% | -56505.0% |
| Net Income | ($33M) | ($30M) | ($545M) | ($61M) | ($28M) | ($26M) | ($39M) | ($26M) |
| Net Margin % | -1908.7% | -3121.8% | -51108.2% | -8154.1% | -3856.6% | -1699.7% | 779160.0% | -65715.0% |
| EBITDA | ($44M) | ($30M) | ($545M) | ($61M) | ($27M) | ($25M) | ($29M) | ($26M) |
| Earnings Per Share (EPS) | $-0.09 | $-0.08 | $-2.45 | $-0.28 | $-0.14 | $-0.15 | $-0.24 | $-0.16 |
| Shares Outstanding (M) | 361M | 357M | 222M | 218M | 197M | 176M | 160M | 161M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($128M) | ($103M) | ($82M) | ($84M) | ($104M) | ($63M) | ($21M) | ($8M) |
| Capital Expenditures (CapEx) | $5M | $1M | $0M | $1M | $1M | $1M | $0M | $0M |
| Free Cash Flow (FCF) | ($133M) | ($104M) | ($83M) | ($85M) | ($105M) | ($64M) | ($21M) | ($8M) |
| FCF Margin % | -2978.8% | -2533.0% | -26796.1% | -26977.1% | -45275.1% | -315.9% | -104.8% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($35M) | ($21M) | ($48M) | ($23M) | ($14M) | ($18M) | ($24M) | ($19M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $5M | $5M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($35M) | ($21M) | ($48M) | ($29M) | ($19M) | ($18M) | ($24M) | ($19M) |
| FCF Margin % | -2070.0% | -2210.7% | -4526.6% | -3821.6% | -2673.3% | -1164.6% | 487680.0% | -48355.0% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $265M | $311M | $159M | $293M | $305M | $414M | $112M | $62M |
| Cash & Cash Equivalents | $169M | $85M | $18M | $45M | $191M | $362M | $97M | $30M |
| Total Liabilities | $88M | $89M | $43M | $49M | $40M | $28M | $16M | $2M |
| Total Debt (Short + Long-Term) | $3M | $0M | $24M | $18M | $15M | $1M | $2M | $0M |
| Total Shareholders' Equity | $176M | $222M | $116M | $243M | $261M | $377M | $91M | $59M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ATAI viewer.
About TickerBase · Data methodology & sources · Privacy · Terms